Published in J Adv Res on May 05, 2017
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med (2016) 5.24
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
Gout. Lancet (2009) 4.33
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis (2006) 4.26
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol (2010) 4.06
A role for uric acid in the progression of renal disease. J Am Soc Nephrol (2002) 3.77
Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol (2008) 3.42
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol (2002) 3.37
Uric acid and long-term outcomes in CKD. Am J Kidney Dis (2009) 2.86
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Uric acid and incident kidney disease in the community. J Am Soc Nephrol (2008) 2.44
Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol (1992) 2.35
Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study. Arthritis Rheum (2013) 2.19
High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care (2010) 2.12
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes (2013) 2.03
Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int (2005) 2.02
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2011) 1.85
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis (2015) 1.84
Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens (2010) 1.80
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis (2015) 1.77
High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 1.74
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol (2012) 1.73
Molecular physiology of urate transport. Physiology (Bethesda) (2005) 1.69
Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol (2009) 1.69
Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis (2010) 1.65
Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis (1982) 1.65
Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant (2013) 1.55
Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant (2003) 1.51
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol (2011) 1.40
US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis (2016) 1.37
Oxygen free radicals and contrast nephropathy. Am J Kidney Dis (1998) 1.28
Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis (2012) 1.26
Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol (2008) 1.25
Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A (2009) 1.23
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care (2011) 1.23
Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis (2010) 1.23
Uric acid as a target of therapy in CKD. Am J Kidney Dis (2012) 1.22
A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant (2011) 1.22
Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol (2014) 1.19
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens (2008) 1.15
HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant (2011) 1.10
Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res (2011) 1.10
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol (2014) 1.09
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep (2013) 1.09
A 'complexity' of urate transporters. Kidney Int (2010) 1.06
Requiem for gouty nephropathy. Kidney Int (1986) 1.02
An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res (2012) 1.01
Characteristics and risk factors of intrarenal arterial lesions in patients with IgA nephropathy. Nephrol Dial Transplant (2005) 0.96
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol (2015) 0.94
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis (2015) 0.93
Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol (1999) 0.91
Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol (2011) 0.91
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Adv Ther (2015) 0.90
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des (2005) 0.88
Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum (2013) 0.88
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab (2015) 0.87
Hyperuricemia and chronic kidney disease: an enigma yet to be solved. Ren Fail (2014) 0.86
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother (2009) 0.86
Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA. Clin Kidney J (2015) 0.86
Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease-A Propensity Score Analysis. PLoS One (2015) 0.84
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant (2001) 0.84
Uricosuric effect of losartan in patients with renal transplants. Transplantation (2001) 0.84
Uric acid induces caspase-1 activation, IL-1β secretion and P2X7 receptor dependent proliferation in primary human lymphocytes. Hippokratia (2013) 0.83
Understanding treatments for gout. Am J Manag Care (2005) 0.81
Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry. Eur J Clin Pharmacol (2014) 0.81
Hyperuricemia is associated with progression of IgA nephropathy. Int Urol Nephrol (2015) 0.79
Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol (2015) 0.78
Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan. Clin Exp Nephrol (2004) 0.78
Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts. Vasc Health Risk Manag (2009) 0.78
Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clin J Am Soc Nephrol (2014) 0.78